Preface

The core message for longevity practice is that vitamin D is a corrective, not an enhancement, intervention: robust RCT evidence shows meaningful benefit only where deficiency or high baseline risk exists (all-cause and cancer mortality in older/institutionalised populations, progression from prediabetes), whereas supplementation of already-replete adults yields no reduction in mortality, cancer incidence, cardiovascular events, fractures or falls.[1][2][3][4][5] Effects on ageing biomarkers (epigenetic clocks, PhenoAge) are hypothesis-generating surrogates not yet linked to hard clinical benefit.[6][7][8] High intermittent bolus dosing is potentially harmful.[9][10]



1. Scope

Covered: use of oral vitamin D (cholecalciferol/D3, with reference to ergocalciferol and calcifediol) for healthspan/longevity aims in community-dwelling adults attending a private UK longevity clinic — mortality, cancer, cardiometabolic, frailty, musculoskeletal and biological-ageing endpoints; assessment, dosing, monitoring, safety.

Not covered: paediatric rickets, established osteoporosis pharmacotherapy, management of overt osteomalacia, hypoparathyroidism, CKD-mineral bone disorder, granulomatous disease management, and vitamin D analogues used as licensed drugs (e.g. paricalcitol). All content is adjunctive to — not a replacement for — NHS primary and secondary care.

Positioning: vitamin D repletion to avoid deficiency is guideline-based and on-label as a nutritional supplement. Use of higher “optimising” targets (e.g. aiming >75–125 nmol/L) or use explicitly to slow biological ageing is off-label/expert-opinion and should be framed as such with the patient.



2. Background and pathophysiology

– Endocrine biology: 25-hydroxyvitamin D [25(OH)D] is the storage form and accepted status biomarker; the active hormone 1,25(OH)₂D binds the vitamin D receptor (VDR), a ligand-activated transcription factor regulating calcium–phosphate homeostasis, immune modulation, and cell proliferation/differentiation.[6][11]

– Longevity-relevant mechanisms (mechanistic plausibility, human data limited): VDR signalling influences myogenic differentiation and neuromuscular junction integrity, immune/inflammasome regulation, and mitochondrial function — pathways that overlap with frailty and immunosenescence. Observational human data link higher 25(OH)D to lower PhenoAge acceleration and one quasi-interventional cohort links initiating supplementation in deficient older adults to slower epigenetic ageing (7-CpG and Horvath clocks).[12][13][7]

– Robust human mechanistic signal: the strongest reproducible clinical-mechanistic link is improvement in glucose regulation in prediabetes (lower fasting/2-hour glucose, higher reversion to normoglycaemia).[14]

Preclinical only (clearly separated — do NOT extrapolate to patients): cell-culture and animal data suggest 1,25(OH)₂D attenuates oxidative stress and senescence via Nrf2 and Klotho induction and modulates DNA methylation, histone modification and microRNAs.[15][6] These are in-vitro/animal findings without confirmatory RCT outcomes.



3. Evidence base and grading

Available evidence is unusually strong for a supplement: multiple large primary-prevention RCTs (VITAL n=25,871; ViDA; D-Health n=21,315; FIND; D2d), several Cochrane and other systematic reviews/meta-analyses, and large prospective cohorts. GRADE-style certainty by outcome:

Outcome	Evidence statement	Certainty (GRADE)	Recommendation
All-cause mortality (general/replete adults)	52-RCT MA (n≈75,454): RR 0.98 (0.95–1.02), I²=0%; USPSTF/USPSTF-report OR 0.96 (0.91–1.02) [1], [2]	High (no benefit)	Recommend against supplementing for mortality benefit in replete adults
All-cause mortality (older/deficient/institutionalised)	Cochrane 38-RCT: RR 0.94 (0.91–0.98); Endocrine Society SR RR 0.96 (0.93–1.00), ~6 fewer deaths/1000 [9], [14], [16]	Moderate (indirectness, small absolute effect)	Conditional benefit limited to at-risk older adults
Cancer mortality	Cochrane RR 0.88 (0.78–0.98); VITAL total cancer death HR 0.83 (0.67–1.02), 0.75 (0.59–0.96) excluding first 2y [1], [3], [9]	Moderate (imprecision, latency-dependent, post hoc)	Conditional — plausible latent benefit; not established for incidence
Cancer incidence	VITAL HR 0.96 (0.88–1.06); ViDA HR 1.01; pooled null [3], [4], [9]	High (no effect)	Recommend against for incidence prevention
Major CVD events	VITAL HR 0.97 (0.85–1.12); 14-RCT RR 1.00 (0.93–1.08); FIND null overall [4], [14], [17], [18]	High (no effect)	Recommend against for CVD prevention
Progression prediabetes → T2D	IPD-MA 3 trials (n=4190) HR 0.85 (0.75–0.96); 3-yr ARR 3.3%; NNT ~30 [19], [20]	Moderate–High	Conditional recommendation to offer in high-risk prediabetes
Fractures / falls	VITAL fractures HR 0.98 (0.89–1.08), falls OR 0.97; D-Health HR 0.94; DO-HEALTH null [14], [21], [22]	High (no effect in replete)	Recommend against in replete adults; correct deficiency
Frailty	Cohort MA: highest vs lowest 25(OH)D RR 0.71 (0.60–0.84) — observational only; RCTs neutral in replete [12], [23], [24]	Low (observational; confounding/reverse causation)	Only correct deficiency; no RCT support for anti-frailty dosing
Epigenetic/biological ageing	Quasi-interventional cohort slower DNAmAA [7]; DO-HEALTH: effect mainly omega-3, vitamin D weak/additive [8]; NHANES cross-sectional [13]	Very low (surrogate, no hard-outcome linkage)	Only in research
T2D prevention in general (non-prediabetic) population	VITAL ancillary: no effect [5]	High (no effect)	Recommend against

Cross-cutting GRADE caveats: most megatrials enrolled largely vitamin D–replete participants (VITAL mean baseline 25(OH)D ~31 ng/mL; only ~10% deficient), producing indirectness for genuinely deficient longevity patients.[21][9][18] Heterogeneity for mortality is low (I²≈0%).[1][16] Publication bias is a concern for small early positive trials and for surrogate-endpoint ageing studies. Bolus/intermittent trials confound “dose” with harmful pharmacokinetics.[9][10]

The VITAL primary endpoints are the clearest illustration of the null result in replete adults. The following figure shows the essentially superimposed cancer and CVD incidence curves:

Figure 2 Cumulative Incidence Rates of Invasive Cancer of Any Type and Major Cardiovascular Events, According to Year of Follow-up, in the Vitamin D Group and Placebo Group.



4. Patient selection and indications

Who may benefit (correction of deficiency / high-risk phenotypes):

– Adults at risk of deficiency: limited sun exposure, darker skin phototypes, veiling, housebound/institutionalised, older age (>70), obesity, malabsorption (coeliac, IBD, bariatric surgery), anticonvulsant/glucocorticoid use.[25][26]

– High-risk prediabetes (meeting ≥2 ADA glycaemic criteria) — the strongest longevity-relevant indication with RCT support.[19][20][14]

– Frail/older adults with documented insufficiency — correct to sufficiency; no benefit from supra-physiological targets.[24][12][21]

– Documented 25(OH)D deficiency on testing regardless of symptoms.

Who is unlikely to benefit:

– Replete, community-dwelling, generally healthy middle-aged adults seeking mortality/cancer/CVD “optimisation” — RCTs show no benefit.[1][3][4][5]

– Athletic individuals seeking performance/longevity beyond correcting deficiency — no robust supporting data.

Exclusion / caution groups: hypercalcaemia, primary hyperparathyroidism, granulomatous disease (sarcoidosis, TB) and lymphoma (extra-renal 1α-hydroxylase → hypersensitivity), nephrolithiasis history, and CKD (needs specialist input).[26]

Regulatory/ethical status:

– Vitamin D as a nutritional supplement to prevent/correct deficiency is on-label/guideline-based.

– “Optimising” to targets >75 nmol/L for longevity, or use to modify epigenetic ageing, is off-label/expert-opinion → adjunctive care with explicit informed consent; epigenetic-clock-driven dosing should be only in research/registry settings.[6][7][8]



5. Assessment and baseline work-up

Pre-intervention:

– History: sun exposure, diet, ethnicity/skin phototype, malabsorption, medications (glucocorticoids, anticonvulsants, thiazides), renal stones, sarcoidosis/granulomatous disease, falls, fracture history.

– Examination: proximal muscle strength/gait, frailty screen (e.g. gait speed, grip, or a frailty index) in older adults.[24]

– Baseline bloods: serum 25(OH)D (status biomarker), corrected calcium, phosphate, renal function/eGFR, and PTH where deficiency or hyperparathyroidism is suspected. Consider HbA1c/fasting glucose to identify prediabetes (an actionable indication).[26][22][20]

– Not recommended: routine population screening of asymptomatic low-risk adults — not cost-effective and no RCT benefit from screening. Test only risk-stratified individuals or those with musculoskeletal symptoms.[27][22][26]

Status thresholds (note UK vs international discordance — preserve, do not harmonise):

– UK SACN: deficiency <25 nmol/L (population-protective floor); some UK experts now argue for <50 nmol/L.[28][29]

– Endocrine Society / IOF: deficiency <50 nmol/L; sufficiency target often ≥75 nmol/L.[29][11]

– Approximate dose–response: each 400 IU/day raises 25(OH)D by ~10 nmol/L; ~400 IU → >25 nmol/L, 800–1000 IU → ~50 nmol/L, 1600–2000 IU → ~75 nmol/L.[10][26]

Baseline documentation for follow-up: 25(OH)D, calcium, eGFR, weight/BMI, glycaemic status, functional/frailty measures. If any biological-ageing biomarker is recorded (epigenetic clock, PhenoAge), document explicitly that it is a research surrogate not validated as a treatment target.[13][6][8]



6. Dosing regimens and practical implementation

Robust human-data-supported regimens (cholecalciferol/D3 preferred):

– Maintenance / deficiency prevention: 800–2000 IU/day; UK official floor is 400 IU/day, but 800–1000 IU/day is required to reliably reach 50 nmol/L.[30][29][26]

– Correcting documented deficiency: loading then maintenance, e.g. 50,000 IU weekly for 6–8 weeks (≈300,000 IU total) or 4000–5000 IU/day for 8 weeks, then 1000–2000 IU/day maintenance; verify with repeat 25(OH)D.[31][26]

– High-risk prediabetes (off-label longevity indication with RCT support): trials used a weighted average ~3500 IU/day (range ~1400–3900); D2d used 4000 IU/day. No single dose is guideline-mandated; 3000–4000 IU/day is representative.[19][20][14]

– Upper intake / safety ceiling: IOM tolerable upper limit 4000 IU/day; the Calgary RCT found 400, 4000 and 10,000 IU/day had a similar overall safety profile over 3 years, but 10,000 IU/day increased hypercalciuria (31%) and caused a small BMD decrease — so routine dosing above 4000 IU/day is not advised.[32][9][10]

Regimens requiring caution or to avoid:

– Avoid high intermittent bolus dosing (e.g. 500,000 IU annually; 60,000 IU monthly): associated with increased falls and fractures and no outcome benefit — daily dosing is more physiological.[14][9][10][22]

– Calcifediol (25(OH)D) achieves faster repletion and may be considered in malabsorption or when rapid correction is needed (specialist/expert use).[30]

Non-pharmacological: sensible sunlight and dietary sources reduce reliance on supplements but cannot be precisely dosed; tanning beds are not recommended by any guideline.[29] In frail older adults, combining vitamin D correction with a home exercise programme (and omega-3) had additive benefit on pre-frailty in DO-HEALTH — driven substantially by exercise/omega-3 rather than vitamin D alone.[21][8]



7. Monitoring, safety and follow-up

Monitoring plan:

– Clinical: symptoms of hypercalcaemia (malaise, polyuria, constipation, confusion), falls, renal colic — have a low threshold to check serum calcium if malaise develops within weeks–months of starting.[26]

– Laboratory: repeat 25(OH)D ~3 months after starting/changing dose; serum calcium and eGFR at baseline and after dose escalation, especially at ≥4000 IU/day. Routine 24-hour urinary calcium is not required for standard doses but consider in stone-formers.[32][26]

– Ageing biomarkers: if tracked, treat as research/monitoring only — do not titrate therapy to epigenetic clock or PhenoAge results, as no RCT links their modification to clinical benefit.[6][7][8]

Timepoints: baseline → 3 months (25[OH]D, calcium) → then 6–12 monthly once stable. Prediabetes patients: monitor HbA1c/glucose 6–12 monthly.[20]

Adverse effects:

– Common, dose-related: hypercalciuria (17% at 400 IU vs 31% at 10,000 IU/day).[32]

– Uncommon/mild: transient mild hypercalcaemia (~3% at 4000, ~9% at 10,000 IU/day; rare at standard doses).[32][9]

– Rare/serious: symptomatic hypercalcaemia and toxicity, essentially confined to sustained intakes >10,000 IU/day with 25(OH)D well above 375 nmol/L. Increased falls/fractures with high intermittent bolus dosing.[10][9]

– Nephrolithiasis: a signal in WHI (with calcium) but not in ViDA/VITAL/D2d; overall RR ~1.0 for intermittent high dose.[14][9]

Actions for abnormal findings: hypercalcaemia → stop vitamin D (and calcium), recheck, investigate for hyperparathyroidism/granulomatous disease; persistent hypercalciuria or stones → reduce dose and reassess; unexplained hypercalcaemia → specialist referral.

Interactions: additive hypercalcaemia risk with calcium supplements and thiazides; reduced levels with enzyme-inducing anticonvulsants, glucocorticoids and orlistat; caution with digoxin (hypercalcaemia potentiates toxicity).[26]

Special populations: CKD/hepatic impairment — altered hydroxylation, specialist input. Frailty/extreme age — correct deficiency, avoid bolus dosing (fall risk).[10] Pregnancy/breastfeeding — 400 IU/day recommended in UK; higher doses only per obstetric guidance (outside longevity scope).



8. Contraindications and cautions

– Absolute contraindications: hypercalcaemia, vitamin D toxicity/hypervitaminosis D, known hypersensitivity.

– Relative / specialist advice needed: primary hyperparathyroidism, granulomatous disease (sarcoidosis, TB) and lymphoma (risk of hypercalcaemia via extra-renal 1α-hydroxylase), active nephrolithiasis, significant CKD, and any unexplained hypercalciuria.[26]

– Harm likely > benefit: high intermittent bolus regimens in older/frail adults (falls, fractures); doses >4000 IU/day sustained without monitoring; supplementing already-replete healthy adults expecting mortality/cancer/CVD reduction (no benefit, small hypercalciuria risk).[1][32][9][10][3]



9. Practical management scenarios

Scenario A — Middle-aged adult, multiple cardiometabolic risk factors, replete 25(OH)D.

– Recommendation: Do not offer vitamin D for CVD/mortality/cancer risk reduction (recommend against, high-certainty null). Consider it only if 25(OH)D is deficient, or if high-risk prediabetes is present.[1][3][4][5]

– Steps: check 25(OH)D + HbA1c/glucose → if prediabetic and high-risk, discuss modest benefit (NNT ~30, ARR ~3% over 3y) and offer ~3000–4000 IU/day with shared decision-making → if replete and normoglycaemic, redirect effort to statins/BP/lifestyle → monitor calcium/25(OH)D if supplemented; stop if hypercalcaemia.[19][20]

Scenario B — Older, frail patient with multimorbidity.

– Recommendation: Offer correction of deficiency to sufficiency (~50 nmol/L) using daily dosing; conditional mortality/frailty rationale from older-adult meta-analyses. Avoid high intermittent bolus dosing (falls/fractures).[14][16][23][24][9][10]

– Steps: measure 25(OH)D, calcium, eGFR, PTH; frailty and falls assessment → if deficient, 800–2000 IU/day (or short loading then maintenance) → combine with exercise ± omega-3 for pre-frailty (evidence mainly from the non-vitamin-D components) → recheck 25(OH)D/calcium at 3 months, then 6–12 monthly.[8][21]

Scenario C — Patient already under specialist care (e.g. osteoporosis, IBD, CKD) using vitamin D as adjunct.

– Recommendation: Consider/continue as adjunct, coordinated with the specialist; restrict autonomy where CKD, malabsorption or bone pharmacotherapy is involved.

– Steps: confirm target and dose with the treating team; in malabsorption consider higher doses or calcifediol; avoid duplicate calcium/vitamin D leading to hypercalcaemia; monitor calcium/eGFR; document that any longevity-target (>75 nmol/L) is off-label and consented. Escalate/refer for unexplained hypercalcaemia, rising creatinine, or stones.[30]



10. Research gaps and future directions

– Optimal target in genuinely deficient longevity patients: megatrials were done in replete cohorts, leaving the deficient population (most relevant to correction) underpowered and indirect.[21][9][18]

– Cancer mortality latency: whether the VITAL/Cochrane cancer-death signal is real requires longer-duration, deficiency-enriched RCTs with mortality as a primary endpoint.[3][9]

– Prediabetes dosing and 25(OH)D target: whether maintaining ≥100–125 nmol/L confers the large risk reductions seen in on-treatment analyses needs a randomised test, not post hoc data.[19][20]

– Pharmacogenomics: VDR polymorphisms (e.g. ApaI) as effect modifiers for T2D prevention are hypothesis-generating and warrant prospective validation.[33]

– Biological-ageing endpoints: epigenetic clocks/PhenoAge changes with vitamin D remain surrogate-only; RCTs integrating molecular endpoints with hard clinical outcomes are needed before any anti-ageing claim. Until then, epigenetic-clock-guided vitamin D dosing should be confined to well-designed trials or registries.[6][7][8]

– UK deficiency threshold: ongoing policy debate over raising the definition from <25 to <50 nmol/L will affect who is treated in UK practice.[28][29]

References

1. Association Between Vitamin D Supplementation and Mortality: Systematic Review and Meta-Analysis. Zhang Y, Fang F, Tang J, et al. BMJ (Clinical Research Ed.). 2019;366:l4673. doi:10.1136/bmj.l4673.
2. Vitamin and Mineral Supplements for the Primary Prevention of Cardiovascular Disease and Cancer. O’Connor EA, Evans CV, Ivlev I, et al. JAMA. 2022;327(23):2334-2347. doi:10.1001/jama.2021.15650.
3. Principal Results of the VITamin D and OmegA-3 TriaL (VITAL) and Updated Meta-Analyses of Relevant Vitamin D Trials. Manson JE, Bassuk SS, Buring JE. The Journal of Steroid Biochemistry and Molecular Biology. 2020;198:105522. doi:10.1016/j.jsbmb.2019.105522.
4. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. Manson JE, Cook NR, Lee IM, et al. The New England Journal of Medicine. 2019;380(1):33-44. doi:10.1056/NEJMoa1809944.
5. Vitamin D supplementation vs. placebo and incident type 2 diabetes in an ancillary study of the randomized Vitamin D and Omega-3 Trial. Tobias DK, Pradhan AD, Duran EK, et al. Nature Communications. 2025;16(1):3332. doi:10.1038/s41467-025-58721-6.
6. Vitamin D-Related Signaling and Epigenetic Regulation: Evidence From Experimental, Observational, and Interventional Studies. Kozłowska H, Cichocka E, Górczyńska-Kosiorz SB, Gumprecht J. Pharmaceuticals (Basel, Switzerland). 2026;19(6):906. doi:10.3390/ph19060906.
7. Vitamin D Supplementation Is Associated With Slower Epigenetic Aging. Vetter VM, Sommerer Y, Kalies CH, et al. GeroScience. 2022;44(3):1847-1859. doi:10.1007/s11357-022-00581-9.
8. Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial. Bischoff-Ferrari HA, Gängler S, Wieczorek M, et al. Nature Aging. 2025;5(3):376-385. doi:10.1038/s43587-024-00793-y.
9. The health effects of vitamin D supplementation: evidence from human studies. Bouillon R, Manousaki D, Rosen C, et al. Nature Reviews. Endocrinology. 2022;18(2):96-110. doi:10.1038/s41574-021-00593-z.
10. Vitamin D Insufficiency. Rosen CJ. The New England Journal of Medicine. 2011;364(3):248-54. doi:10.1056/NEJMcp1009570.
11. Rickets. Elder CJ, Bishop NJ. Lancet (London, England). 2014;383(9929):1665-1676. doi:10.1016/S0140-6736(13)61650-5.
12. Vitamin D and Frailty: Clinical Evidence, Mechanistic Insights, and Translational Challenges. Viola V, Tramontana F, Leanza G, Faraj M, Napoli N. Metabolism: Clinical and Experimental. 2026;183:156697. doi:10.1016/j.metabol.2026.156697.
13. Association of 25(OH)D serum level with biological aging: A Cross-Sectional Study of 2007–2016 NHANES surveys. Feng Y, Yu L, Wang J. PloS One. 2025;20(8):e0328107. doi:10.1371/journal.pone.0328107.
14. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. Demay MB, Pittas AG, Bikle DD, et al. The Journal of Clinical Endocrinology and Metabolism. 2024;109(8):1907-1947. doi:10.1210/clinem/dgae290.
15. The Role of Vitamin D on Redox Regulation and Cellular Senescence. Sosa-Díaz E, Hernández-Cruz EY, Pedraza-Chaverri J. Free Radical Biology & Medicine. 2022;193(Pt 1):253-273. doi:10.1016/j.freeradbiomed.2022.10.003.
16. Vitamin D supplementation for prevention of mortality in adults. Bjelakovic G, Gluud LL, Nikolova D, et al. The Cochrane Database of Systematic Reviews. 2014;(1):CD007470. doi:10.1002/14651858.CD007470.pub3.
17. Vitamin D supplementation and prevention of cardiovascular disease and cancer in the Finnish Vitamin D Trial: a randomized controlled trial. Virtanen JK, Nurmi T, Aro A, et al. The American Journal of Clinical Nutrition. 2022;115(5):1300-1310. doi:10.1093/ajcn/nqab419.
18. Vitamin D, Calcium Supplements, And Implications for Cardiovascular Health: JACC Focus Seminar. Michos ED, Cainzos-Achirica M, Heravi AS, Appel LJ. Journal of the American College of Cardiology. 2021;77(4):437-449. doi:10.1016/j.jacc.2020.09.617.
19. Vitamin D and Risk for Type 2 Diabetes in People With Prediabetes : A Systematic Review and Meta-Analysis of Individual Participant Data From 3 Randomized Clinical Trials. Pittas AG, Kawahara T, Jorde R, et al. Annals of Internal Medicine. 2023;176(3):355-363. doi:10.7326/M22-3018.
20. Mini-Review. Vitamin D for the Prevention of Type 2 Diabetes: Evidence and Implications. Amrein K, Kim SH, Brath H, Fasching P, Pittas AG. Metabolism: Clinical and Experimental. 2026;178:156566. doi:10.1016/j.metabol.2026.156566.
21. The Effects of Vitamin D Supplementation on Musculoskeletal Health: The VITAL and DO-Health Trials. LeBoff MS, Bischoff-Ferrari HA. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2023;78(Suppl 1):73-78. doi:10.1093/gerona/glad073.
22. Osteoporosis. Ye C, Ebeling P, Kline G. Lancet (London, England). 2025;406(10514):2003-2016. doi:10.1016/S0140-6736(25)01385-6.
23. Association Between 25-Hydroxy Vitamin D Levels and Risk of Frailty and Pre-Frailty in Elderly Adults: A Systematic Review and Dose-Response Meta-Analysis of Epidemiologic Studies With GRADE Assessment. Khakbaz M, Moradmand Z, Ziaei R, Moradi Baniasadi M, Saneei P. Journal of Translational Medicine. 2025;23(1):1401. doi:10.1186/s12967-025-07415-0.
24. Association Between Vitamin D, Frailty, and Progression of Frailty in Community-Dwelling Older Women. Buchebner D, Bartosch P, Malmgren L, et al. The Journal of Clinical Endocrinology and Metabolism. 2019;104(12):6139-6147. doi:10.1210/jc.2019-00573.
25. Vitamin D: What’s the Proper Dose?. Birge SJ. Journal of the American Geriatrics Society. 2026;. doi:10.1111/jgs.70455.
26. A view on vitamin D: a pleiotropic factor?. Giustina A, Lazaretti-Castro M, Martineau AR, et al. Nature Reviews. Endocrinology. 2024;20(4):202-208. doi:10.1038/s41574-023-00942-0.
27. Screening for Vitamin D Deficiency in Adults: US Preventive Services Task Force Recommendation Statement. US Preventive Services Task Force, Krist AH, Davidson KW, et al. JAMA. 2021;325(14):1436-1442. doi:10.1001/jama.2021.3069.
28. Vitamin D in the UK: An Urgent Call to Redefine the Threshold for Deficiency. Christie S, Uday S, Hill TR, et al. Frontiers in Endocrinology. 2026;17:1870408. doi:10.3389/fendo.2026.1870408.
29. Comparative analysis of nutritional guidelines for vitamin D. Bouillon R. Nature Reviews. Endocrinology. 2017;13(8):466-479. doi:10.1038/nrendo.2017.31.
30. Role of Vitamin D Supplementation in the Management of Musculoskeletal Diseases: Update From an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) Working Group. Chevalley T, Brandi ML, Cashman KD, et al. Aging Clinical and Experimental Research. 2022;34(11):2603-2623. doi:10.1007/s40520-022-02279-6.
31. Italian Association of Clinical Endocrinologists (AME) and Italian Chapter of the American Association of Clinical Endocrinologists (AACE) Position Statement: Clinical Management of Vitamin D Deficiency in Adults. Cesareo R, Attanasio R, Caputo M, et al. Nutrients. 2018;10(5):E546. doi:10.3390/nu10050546. Copyright License: CC BY.
32. Safety of High-Dose Vitamin D Supplementation: Secondary Analysis of a Randomized Controlled Trial. Billington EO, Burt LA, Rose MS, et al. The Journal of Clinical Endocrinology and Metabolism. 2020;105(4):dgz212. doi:10.1210/clinem/dgz212.
33. Vitamin D Receptor Polymorphisms and the Effect of Vitamin D Supplementation on Diabetes Risk Among Adults With Prediabetes. Dawson-Hughes B, Huggins GS, Nelson J, et al. JAMA Network Open. 2026;9(4):e267332. doi:10.1001/jamanetworkopen.2026.7332.